GLP1R and type 2 diabetes mellitus: Twenty-four patients with obesity and T2DM undergoing insulin therapy were randomly assigned to receive either exenatide (a glucagon-like peptide-1 receptor agonist) or a placebo twice daily for 12 weeks.